Plain-English translation of NCT06847321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are studying whether a medication called can help slow or improve symptoms of Alzheimer's disease in people who have a specific gum bacteria infection. This is a Phase 2 trial, meaning the medication has shown early promise and is now being tested in a larger group to see if it's safe and effective. You would receive either the medication at one of two doses or a placebo (inactive pill) for 48 weeks.
Recent research suggests that a common gum bacteria may play a role in some cases of Alzheimer's disease. This trial is exploring whether treating this bacterial infection with a new medication might help slow cognitive decline in people with Alzheimer's.
You likely qualify if…
You likely don't qualify if…
You would first go through a screening period of up to 12 weeks with at least two visits to confirm you qualify. If you do, you would be randomly assigned to take either the medication at a lower dose, the medication at a higher dose, or a placebo pill once daily for 48 weeks. During this time, you would visit the clinic regularly for check-ups, memory tests, and blood work. After the 48-week treatment period ends, you would have one final follow-up visit about 4 weeks later to make sure you're doing well.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States